MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · USD

$12.3

+0.39 (+3.3%)· Recorded snapshot

Market cap	1B
Net income (ttm)	-263.7M
EPS (ttm)	-$3.81
Shares out	85.1M
Volume	1,035,378
Beta	1.08

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -263.7M
EPS (ttm): -$3.81
Market cap: 1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-67.5

P25 -113.8P50 -46.5P75 -0.9

ROIC-34.8

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All MLTX indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001821586
Company name	MoonLake Immunotherapeutics
Country	Switzerland
Country code	US
CUSIP number	61559X104
Earnings date	2026-11-09
Earnings time	bmo
Employees	130
Employees change	30
Employees growth	30%
Enterprise value	$613M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2021
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	KY61559X1045
Last 10-K release date	2026-02-25
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$12.32
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	MLTX
Tags	pharmaceuticals
Website	https://www.moonlaketx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-30.96%
FCF / EV yield	-36.99%
FCF yield	-21.56%
Forward EV/Sales	2,314.68x
Forward P/S	3,970.57x
P/B ratio	2.33x
Price / tangible book value	2.44x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2M
ROA	-32.44%
ROCE	-50.77%
ROE	-67.47%
ROIC	-34.81%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$0
Depreciation and amortization	$3.2M
EBIT	$-268.3M
EBITDA	$-265.1M
EPS	$-3.81
FCF per share	$-2.65
Financing cash flow	$338.1M
Free cash flow	$-225.2M
Free cash flow minus SBC	$-248.4M
Income taxes	$1.1M
Investing cash flow	$58.9M
Net borrowing	$24.5M
Net cash flow	$171.2M
Net income	$-263.7M
Operating cash flow minus SBC	$-248.4M
Operating income	$-268.3M
Stock-based compensation	$23.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$5.12
Debt / equity	0.24
Interest coverage	-26.59
Long-term assets	$3.9M
Long-term liabilities	$100.4M
Net cash (debt)	$435.5M
Net cash / market cap	41.7%
Net cash growth	24.67%
Net debt / equity	-1.02
Piotroski F-Score	1
Property, plant and equipment	$2.6M
Shareholders' equity	$428.2M
Tangible book value	$428.2M
Tangible book value per share	$5.12
Total assets	$573.9M
Total cash	$537M
Total debt	$101.5M
Total liabilities	$145.8M
WACC	9.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$570M
Current liabilities	$45.4M
Current ratio	12.56
Net working capital	$-11.1M
Quick ratio	11.98
Working capital	$524.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-9.53%
Dividend yield	0%
Shareholder yield	-9.53%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$16.40
1D price change	3.27%
1M price change	2.33%
1M total return	2.33%
1W price change	15.68%
1W total return	15.68%
1Y price change	22.34%
1Y return CAGR	22.36%
1Y total return	22.34%
20-day SMA	$10.97
200-day SMA	$16.52
3M price change	-38.03%
3M total return	-38.03%
3Y price change	-75.35%
3Y return CAGR	-37.29%
3Y total return	-75.35%
50-day SMA	$12.69
50-day SMA vs 200-day SMA	50under200
52-week high	$23.29
52-week high date	2026-06-22
52-week low	$9.37
52-week low date	2025-10-29
5Y price change	23.2%
5Y return CAGR	4.26%
5Y total return	23.2%
6M price change	-26.88%
6M total return	-26.88%
All-time high	$64.98
All-time high date	2024-02-12
All-time low	$4.25
All-time low date	2022-05-16
Average true range (ATR)	$0.74
Average volume	1.9M
Beta (1Y)	1.55
Beta (2Y)	0.67
Beta (5Y)	1.08
Change from 52-week high	-47.1%
Change from 52-week low	31.48%
Change from all-time high	-81.04%
Change from all-time low	189.88%
Change from open	4.23%
Day's gap	-0.92%
Dollar volume	$12.8M
High price	$12.37
Low price	$11.75
Monthly RSI	38.24
Open price	$11.82
Position in 52-week range	91.94%
Premarket change	2.85%
Premarket close	$11.93
Premarket price	$12.27
Premarket volume	159
Previous close	$11.93
Price vs 150-day SMA	-24.87%
Price vs 20-day SMA	12.31%
Price vs 200-day SMA	-25.4%
Price vs 50-day SMA	-2.9%
Relative volume	0.55
RSI	56.88
Sharpe ratio	0.57
Sharpe ratio (3Y)	0.17
Sharpe ratio (5Y)	0.66
Sortino ratio	1.13
Sortino ratio (3Y)	0.28
Sortino ratio (5Y)	1.01
Volume	1M
Weekly RSI	38.88
YTD price change	-6.53%
YTD total return	-6.53%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.5M
Float percentage	65.18%
Shares change (QoQ)	3.71%
Shares change (YoY)	9.53%
Shares held by insiders	7.8%
Shares held by institutions	60.34%
Shares outstanding	85.1M
Short % of float	14.51%
Short % of shares	9.46%
Short ratio	4.7 days

Deeper analysis on MLTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this MLTX report

Is a complete MLTX research report available?

No complete published report is available for MoonLake Immunotherapeutics (MLTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

MoonLake Immunotherapeutics (MLTX)

Price

Financial snapshot

Fair-value bridge

Latest news · MLTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All MLTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on MLTX

Frequently asked questions